Acute myeloid leukemia (AML) is an uncommon but potentially catastrophic diagnosis with
historically high mortality rates. The standard of care treatment remained unchanged for …

Chimeric antigen receptor (CAR)-T cell therapy is a progressive new pillar in immune cell
therapy for cancer. It has yielded remarkable clinical responses in patients with B-cell …

Chimeric antigen receptor T (CAR-T) cell therapy is regarded as an effective solution for
relapsed or refractory tumors, particularly for hematological malignancies. Although the …

Acute myeloid leukemia (AML) is a serious, life-threatening, and hardly curable
hematological malignancy that affects the myeloid cell progenies and challenges patients of …

Highlights•CAR T cells are associated with unique side-effects.•Cytokine release syndrome
(CRS), immune effector cell-associated neurotoxicity syndrome (ICANS) and cytopenias are …

Acute myeloid leukemia (AML) is a rapidly progressive malignancy without effective
therapies for refractory disease. So far, chimeric antigen receptor (CAR) T cell therapy in …

T cells play a key role in cell-mediated immunity, and strategies to genetically modify T cells,
including chimeric antigen receptor (CAR) T cell therapy and T cell receptor (TCR) T cell …

Chimeric antigen receptor (CAR) T cells targeting CD19 mediate potent effects in relapsed
and/or refractory pre–B cell acute lymphoblastic leukemia (B-ALL), but antigen loss is a …

Adaptive immunity, orchestrated by B-cells and T-cells, plays a crucial role in protecting the
body from pathogenic invaders and can be used as tools to enhance the body's defense …

Adenosine is an immunosuppressive factor that limits anti-tumor immunity through the
suppression of multiple immune subsets including T cells via activation of the adenosine …